Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' ANASETTI C' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 167 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Pei, J; Akatsuka, Y; Anasetti, C; Lin, MT; Petersdorf, EW; Hansen, JA; Martin, PJ
      Generation of HLA-C-specific cytotoxic T cells in association with marrow graft rejection: Analysis of alloimmunity by T-cell cloning and testing of T-cell-receptor rearrangements

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    2. Deeg, HJ; Amylon, MD; Harris, RE; Collins, R; Beatty, PG; Feig, S; Ramsay, N; Territo, M; Khan, SP; Pamphilon, D; Leis, JF; Burdach, S; Anasetti, C; Hackman, R; Storer, B; Mueller, B
      Marrow transplants from unrelated donors for patients with aplastic anemia: Minimum effective dose of total body irradiation

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    3. Anasetti, C; Petersdorf, EW; Martin, PJ; Woolfrey, A; Hansen, JA
      Trends in transplantation of hematopoietic stem cells from unrelated donors

      CURRENT OPINION IN HEMATOLOGY
    4. Zerr, DM; Gooley, TA; Yeung, L; Huang, ML; Carpenter, P; Wade, JC; Corey, L; Anasetti, C
      Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients

      CLINICAL INFECTIOUS DISEASES
    5. Petersdorf, E; Anasetti, C; Martin, PJ; Woolfrey, A; Smith, A; Mickelson, E; Malkki, M; Lin, MT; Hansen, JA
      Genomics of unrelated-donor hematopoietic cell transplantation

      CURRENT OPINION IN IMMUNOLOGY
    6. Witherspoon, RP; Deeg, HJ; Storer, B; Anasetti, C; Storb, R; Appelbaum, FR
      Hematopoietic stern-cell transplantation for treatment-related leukemia ormyelodysplasia

      JOURNAL OF CLINICAL ONCOLOGY
    7. Yu, XZ; Carpenter, P; Anasetti, C
      Advances in transplantation tolerance

      LANCET
    8. Yu, XZ; Bidwell, SJ; Martin, PJ; Anasetti, C
      Anti-CD3 epsilon F(ab ')(2) prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens

      JOURNAL OF IMMUNOLOGY
    9. Petersdorf, EW; Gooley, T; Malkki, M; Anasetti, C; Martin, P; Woolfrey, A; Smith, A; Mickelson, E; Hansen, JA
      The biological significance of HLA-DP gene variation in haematopoietic cell transplantation

      BRITISH JOURNAL OF HAEMATOLOGY
    10. Jurado, M; Deeg, HJ; Gooley, T; Anasetti, C; Chauncey, T; Flowers, MED; Myerson, D; Storb, R; Appelbaum, FR
      Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia

      BRITISH JOURNAL OF HAEMATOLOGY
    11. Kollman, C; Howe, CWS; Anasetti, C; Antin, JH; Davies, SM; Filipovich, AH; Hegland, J; Kamani, N; Kernan, NA; King, R; Ratanatharathorn, V; Weisdorf, D; Confer, DL
      Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age

      BLOOD
    12. Ohishi, K; Varnum-Finney, B; Serda, RE; Anasetti, C; Bernstein, ID
      The Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells

      BLOOD
    13. Kansu, E; Gooley, T; Flowers, MED; Anasetti, C; Deeg, HJ; Nash, RA; Sanders, JE; Witherspoon, RP; Appelbaum, FR; Storb, R; Martin, PJ
      Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial

      BLOOD
    14. Lee, SJ; Klein, JP; Anasetti, C; Antin, JH; Loberiza, FR; Bowell, BJ; LeMaistre, CF; Litzow, MR; Marks, D; Waller, EK; Matlack, M; Giralt, S; Horowitz, MM
      The effect of pretransplant interferon therapy on the outcome of unrelateddonor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase

      BLOOD
    15. Cornelissen, JJ; Carston, M; Kollman, C; King, R; Dekker, AW; Lowenberg, B; Anasetti, C
      Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factorsdetermining outcome

      BLOOD
    16. Carnevale-Schianca, F; Martin, P; Sullivan, K; Flowers, M; Gooley, T; Anasetti, C; Deeg, J; Furlong, T; McSweeney, P; Storb, R; Nash, RA
      Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    17. Flowers, MED; Leisenring, W; Beach, K; Riddell, S; Radich, JP; Higano, CS; Rowley, SD; Chauncey, TR; Bensinger, WI; Sanders, JE; Anasetti, C; Storb, R; Wade, J; Appelbaum, FR; Martin, PJ
      Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion forrecurrent chronic myeloid leukemia after bone marrow transplantation

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    18. Radich, JP; Gooley, T; Sanders, JE; Anasetti, C; Chauncey, T; Appelbaum, FR
      Second allogeneic transplantation after failure of first autologous transplantation

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    19. Sierra, J; Bjerke, J; Hansen, J; Martin, P; Petersdorf, E; Woolfrey, A; Anasetti, C
      Marrow transplants from unrelated donors as treatment for acute leukemia

      LEUKEMIA & LYMPHOMA
    20. Anasetti, C; Petersdorf, EW; Martin, PJ; Woolfrey, A; Hansen, JA
      Improving availability and safety of unrelated donor transplants

      CURRENT OPINION IN ONCOLOGY
    21. Anasetti, C
      Transplantation of hematopoietic stem cells from alternate donors in acutemyelogenous leukemia

      LEUKEMIA
    22. Furlong, T; Storb, R; Anasetti, C; Appelbaum, FR; Deeg, HJ; Doney, K; Martin, P; Sullivan, K; Witherspoon, R; Nash, RA
      Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acutegraft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities

      BONE MARROW TRANSPLANTATION
    23. Sierra, J; Storer, B; Hansen, JA; Martin, PJ; Petersdorf, EW; Woolfrey, A; Matthews, D; Sanders, JE; Storb, R; Appelbaum, FR; Anasetti, C
      Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience

      BONE MARROW TRANSPLANTATION
    24. Mickelson, EM; Petersdorf, E; Anasetti, C; Martin, P; Woolfrey, A; Hansen, JA
      HLA matching in hematopoietic cell transplantation

      HUMAN IMMUNOLOGY
    25. Hansen, JA; Petersdorf, E; Martin, PJ; Woolfry, A; Anasetti, C
      Impact of HLA matching on hematopoietic cell transplants from unrelated donors

      VOX SANGUINIS
    26. Anasetti, C; Petersdorf, EW; Martin, PJ; Woolfrey, A; Hansen, JA
      Transplantation of hematopoietic stem cells from unrelated volunteer donors

      TRANSPLANTATION PROCEEDINGS
    27. Carpenter, PA; Tso, JY; Press, OW; Yu, XZ; Anasetti, C
      Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo

      TRANSPLANTATION PROCEEDINGS
    28. Yu, XZ; Anasetti, C
      Enhancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenetic anti-CD3 epsilon F(ab ')(2)

      TRANSPLANTATION
    29. Carpenter, PA; Pavlovic, S; Tso, JY; Press, OW; Gooley, T; Yu, XZ; Anasetti, C
      Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells

      JOURNAL OF IMMUNOLOGY
    30. Yu, XZ; Bidwell, SJ; Martin, PJ; Anasetti, C
      CD28-Specific antibody prevents graft-versus-host disease in mice

      JOURNAL OF IMMUNOLOGY
    31. Zang, DY; Deeg, HJ; Gooley, T; Anderson, JE; Anasetti, C; Sanders, J; Myerson, D; Storb, R; Appelbaum, F
      Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation

      BRITISH JOURNAL OF HAEMATOLOGY
    32. Nash, RA; Antin, JH; Karanes, C; Fay, JW; Avalos, BR; Yeager, AM; Przepiorka, D; Davies, S; Petersen, FB; Bartels, P; Buell, D; Fitzsimmons, W; Anasetti, C; Storb, R; Ratanatharathorn, V
      Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors

      BLOOD
    33. Davies, SM; Kollman, C; Anasetti, C; Antin, JH; Gajewski, J; Casper, JT; Nademanee, A; Noreen, H; King, R; Confer, D; Kernan, NA
      Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program

      BLOOD
    34. Koc, S; Leisenring, W; Flowers, MED; Anasetti, C; Deeg, HJ; Nash, RA; Sanders, JE; Witherspoon, RP; Appelbaum, FR; Storb, R; Martin, PJ
      Thalidomide for treatment of patients with chronic graft-versus-host disease

      BLOOD
    35. Ohishi, K; Varnum-Finney, B; Flowers, D; Anasetti, C; Myerson, D; Bernstein, ID
      Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1

      BLOOD
    36. Arpinati, M; Green, CL; Heimfeld, S; Heuser, JE; Anasetti, C
      Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells

      BLOOD
    37. McGlave, PB; Shu, XO; Wen, WQ; Anasetti, C; Nadermanee, A; Champlin, R; Antin, JH; Kernan, NA; King, R; Weisdorf, DJ
      Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9years' experience of the National Marrow Donor Program

      BLOOD
    38. Deeg, HJ; Shulman, HM; Anderson, JE; Bryant, EM; Gooley, TA; Slattery, JT; Anasetti, C; Fefer, A; Storb, R; Appelbaum, FR
      Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age

      BLOOD
    39. Matsumoto, K; Anasetti, C
      The role of T cell costimulation by CD80 in the initiation and maintenanceof the immune response to human leukemia

      LEUKEMIA & LYMPHOMA
    40. Petersdorf, EW; Mickelson, EM; Anasetti, C; Martin, PJ; Woolfrey, AE; Hansen, JA
      Effect of HLA mismatches on the outcome of hematopoietic transplants

      CURRENT OPINION IN IMMUNOLOGY
    41. Cole, MS; Stellrecht, KE; Shi, JD; Homola, M; Hsu, DH; Anasetti, C; Vasquez, M; Tso, JY
      HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro

      TRANSPLANTATION
    42. Yu, XZ; Bidwell, S; Martin, PJ; Anasetti, C
      Visualization, fate, and pathogenicity of antigen-specific CD8(+) T cells in the graft-versus-host reaction

      JOURNAL OF IMMUNOLOGY
    43. Zhu, L; Yu, X; Akatsuka, Y; Cooper, JA; Anasetti, C
      Role of mitogen-activated protein kinases in activation-induced apoptosis of T cells

      IMMUNOLOGY
    44. Martin, PJ; Rowley, SD; Anasetti, C; Chauncey, TR; Gooley, T; Petersdorf, EW; van Burik, J; Flowers, MED; Storb, R; Appelbaum, FR; Hansen, JA
      A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients

      BLOOD
    45. YU XZ; MARTIN PJ; ANASETTI C
      ROLE OF CD28 IN ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD)

      The FASEB journal
    46. PETERSDORF E; ANASETTI C; SERVIDA P; MARTIN P; HANSEN J
      EFFECT OF HLA MATCHING ON OUTCOME OF RELATED AND UNRELATED DONOR TRANSPLANTATION THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA

      Hematology/oncology clinics of North America
    47. LEE SJ; ANASETTI C; HOROWITZ MM; ANTIN JH
      INITIAL THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA - PLAYING THE ODDS

      Journal of clinical oncology
    48. RONDELLI D; RASPADORI D; ANASETTI C; BANDINI G; LEMOLI RM; ARPINATI M; RE F; MORELLI A; BACCINI C; ZACCARIA A; TURA S
      ALLOIMMUNE FUNCTIONS OF HEALTHY DONOR G-CSF MOBILIZED BLOOD-CELLS

      Experimental hematology
    49. RONDELLI D; RASPADORI D; ANASETTI C; BANDINI G; RE F; ARPINATI M; STANZANI M; MORELLI A; BACCINI C; ZACCARIA A; LEMOLI RM; TURA S
      ALLOANTIGEN PRESENTING CAPACITY, T-CELL ALLOREACTIVITY AND NK FUNCTION OF G-CSF-MOBILIZED PERIPHERAL-BLOOD CELLS

      Bone marrow transplantation
    50. MARTIN P; NASH R; SANDERS J; LEISENRING W; ANASETTI C; DEEG HJ; STORB R; APPELBAUM F
      REPRODUCIBILITY IN RETROSPECTIVE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC MARROW TRANSPLANTATION

      Bone marrow transplantation
    51. RONDELLI D; ANASETTI C; FORTUNA A; RATTA M; ARPINATI M; BANDINI G; LEMOLI RM; TURA S
      T-CELL ALLOREACTIVITY INDUCED BY NORMAL G-CSF-MOBILIZED CD34(-CELLS()BLOOD)

      Bone marrow transplantation
    52. HANSEN JA; GOOLEY TA; MARTIN PJ; APPELBAUM F; CHAUNCEY TR; CLIFT RA; PETERSDORF EW; RADICH J; SANDERS JE; STORB RF; SULLIVAN KM; ANASETTI C
      BONE-MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID-LEUKEMIA

      The New England journal of medicine
    53. REN S; KALHORN TF; MCDONALD GB; ANASETTI C; APPELBAUM FR; SLATTERY JT
      PHARMACOKINETICS OF CYCLOPHOSPHAMIDE AND ITS METABOLITES IN BONE-MARROW TRANSPLANTATION PATIENTS

      Clinical pharmacology and therapeutics
    54. MARTIN PJ; SCHOCH G; GOOLEY T; ANASETTI C; DEEG HJ; NASH R; SANDERS J; STORB R; APPELBAUM F
      METHODS FOR ASSESSMENT OF GRAFT-VERSUS-HOST DISEASE

      Blood
    55. STUCKI A; LEISENRING W; SANDMAIER BM; SANDERS J; ANASETTI C; STORB R
      DECREASED REJECTION AND IMPROVED SURVIVAL OF FIRST AND 2ND MARROW TRANSPLANTS FOR SEVERE APLASTIC-ANEMIA (A 26-YEAR RETROSPECTIVE ANALYSIS)

      Blood
    56. YU XZ; MARTIN PJ; ANASETTI C
      ROLE OF CD28 IN ACUTE GRAFT-VERSUS-HOST DISEASE

      Blood
    57. MORTON AJ; GOOLEY T; HANSEN JA; APPELBAUM FR; BRUEMMER B; BJERKE JW; CLIFT R; MARTIN PJ; PETERSDORF EW; SANDERS JE; STORB R; SULLIVAN KM; WOOLFREY A; ANASETTI C
      ASSOCIATION BETWEEN PRETRANSPLANT INTERFERON-ALPHA AND OUTCOME AFTER UNRELATED DONOR MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE

      Blood
    58. LEE SJ; ANASETTI C; KUNTZ KM; PATTEN J; ANTIN JH; WEEKS JC
      THE COSTS AND COST-EFFECTIVENESS OF UNRELATED DONOR BONE-MARROW TRANSPLANTATION FOR CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

      Blood
    59. PETERSDORF EW; GOOLEY TA; ANASETTI C; MARTIN PJ; SMITH AG; MICKELSON EM; WOOLFREY AE; HANSEN JA
      OPTIMIZING OUTCOME AFTER UNRELATED MARROW TRANSPLANTATION BY COMPREHENSIVE MATCHING OF HLA CLASS-I AND CLASS-II ALLELES IN THE DONOR AND RECIPIENT

      Blood
    60. WOOLFREY AE; GOOLEY TA; SIEVERS EL; MILNER LA; ANDREWS RG; WALTERS M; HOFFMEISTER P; HANSEN JA; ANASETTI C; BRYANT E; APPELBAUM FR; SANDERS JE
      BONE-MARROW TRANSPLANTATION FOR CHILDREN LESS-THAN 2 YEARS OF AGE WITH ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROME

      Blood
    61. RYNCARZ RE; ANASETTI C
      EXPRESSION OF CD86 ON HUMAN MARROW CD34(+) CELLS IDENTIFIES IMMUNOCOMPETENT COMMITTED PRECURSORS OF MACROPHAGES AND DENDRITIC CELLS

      Blood
    62. CLIFT RA; ANASETTI C
      ALLOGRAFTING FOR CHRONIC MYELOID-LEUKEMIA

      Bailliere's clinical haematology
    63. PEI J; AKATSUKA Y; ANASETTI C; PETERSDORF EW; DAVIS J; GARCIA M; FARRAND A; SMITH A; LIN MT; HANSEN JA
      CHARACTERIZATION OF CYTOTOXIC T-CELLS THAT RECOGNIZE DONOR HLA-C ALLOANTIGENS AS THE CAUSE OF GRAFT-REJECTION AFTER MARROW TRANSPLANTATION

      Human immunology
    64. HANSEN JA; PETERSDORF E; MARTIN PJ; ANASETTI C
      HEMATOPOIETIC STEM-CELL TRANSPLANTS FROM UNRELATED DONORS

      Immunological reviews
    65. COLE MS; ANASETTI C; TSO JY
      HUMAN IGG2 VARIANTS OF CHIMERIC ANTI-CD3 ARE NONMITOGENIC TO T-CELLS

      The Journal of immunology
    66. SIERRA J; RADICH J; HANSEN JA; MARTIN PJ; PETERSDORF EW; BJERKE J; BRYANT E; NASH RA; SANDERS JE; STORB R; SULLIVAN KM; APPELBAUM FR; ANASETTI C
      MARROW TRANSPLANTS FROM UNRELATED DONORS FOR TREATMENT OF PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA

      Blood
    67. FURLONG T; STORB R; ANASETTI C; APPELBAUM F; DEEG HJ; DONEY K; MARTIN P; SULLIVAN KM; WITHERSPOON R; NASH RA
      CONVERSION TO FK506 FOR CYCLOSPORINE (CSP)-RESISTANT ACUTE GVHD OR CSP-ASSOCIATED TOXICITY

      Blood
    68. NASH RA; FURLONG T; STORB R; ANASETTI C; APPELBAUM FR; DEEG HJ; DONEY K; MARTIN P; WITHERSPOON R; SULLIVAN KM
      MYCOPHENOLATE MOFETIL (MMF) AS SALVAGE TREATMENT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT) - SAFETY ANALYSIS

      Blood
    69. LEE SJ; ANASETTI C; KUNTZ KM; PATTEN J; ANTIN JH; WEEKS JC
      THE COST-EFFECTIVENESS OF UNRELATED DONOR BONE-MARROW TRANSPLANTATION(URD BMT) FOR CHRONIC MYELOGENOUS LEUKEMIA (CML)

      Blood
    70. MORTON AJ; GOOLEY T; HANSEN JA; APPELBAUM FR; BJERKE JW; CLIFT R; MARTIN PJ; PETERSDORF EW; SANDERS JE; STORB R; SULLIVAN KM; ANASETTI C
      IMPACT OF PRETRANSPLANT INTERFERON-ALPHA (IFN-ALPHA) ON OUTCOME OF UNRELATED DONOR MARROW TRANSPLANTS FOR CHRONIC MYELOID-LEUKEMIA (CML) INFIRST CHRONIC PHASE

      Blood
    71. CARPENTER PA; ANASETTI C
      ACTIVATION-INDUCED T-CELL DEATH DEPENDS ON SUSTAINED OCCUPANCY OF THETCR

      Blood
    72. YEAGER AM; AMYLON M; WAGNER J; CALDERWOOD S; ANASETTI C; SENDER L; JACOBS C; BENYUNES M
      ALLOGENEIC STEM-CELL TRANSPLANTATION FROM HLA-HAPLOIDENTICAL RELATIVES AS TREATMENT FOR CHILDREN WITH HEMATOLOGIC MALIGNANCY - A PHASE I IISTUDY USING MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS (PBPCS) THAT HAVE UNDERGONE CD34 SELECTION FOLLOWED BY CD2 DEPLETION/

      Blood
    73. DAVIES SM; CONFER D; KOLLMAN C; ANASETTI C; ANTIN J; GAJEWSKI J; CASPER JT; NADEMANEE A; NOREEN H; KING R; KERNAN NA
      ENGRAFTMENT OF UNRELATED DONOR BONE-MARROW - A REPORT FROM THE NATIONAL MARROW DONOR PROGRAM (NMDP)

      Blood
    74. DEEG HJ; SCHOCH G; RAMSAY N; HARRIS R; CASTROMALASPINA H; COLLINS R; GAJEWSKI J; TERRITO M; CASPER J; MUELLER B; ANASETTI C; KING R
      MARROW TRANSPLANTATION FROM UNRELATED DONORS FOR PATIENTS WITH APLASTIC-ANEMIA (AA) WHO FAILED IMMUNOSUPPRESSIVE THERAPY

      Blood
    75. RYNCARZ RE; ANASETTI C
      EXPRESSION OF CD86 ON HUMAN MARROW CD34+ CELLS IDENTIFIES IMMUNOCOMPETENT COMMITTED PRECURSORS OF MACROPHAGES AND DENDRITIC CELLS

      Blood
    76. STUCKI A; LEISENRING W; SANDMAIER BM; SANDERS J; ANASETTI C; STORB R
      INCREASING SURVIVAL FOR SEVERE APLASTIC-ANEMIA PATIENTS WHO UNDERGO A2ND MARROW TRANSPLANT AFTER REJECTION OF THE FIRST GRAFT

      Blood
    77. NASH RA; ANTIN J; KARANES C; FAY J; AVALOS B; YEAGER AM; PRZEPIORKA D; DAVIES S; PETERSEN F; BUELL D; FITZSIMMONS W; BARTELS P; HANSEN J; ANASETTI C; STORB R; RATANATHARATHORN V
      PHASE-III STUDY COMPARING TACROLIMUS (FK506) WITH CYCLOSPORINE (CSP) FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER MARROWTRANSPLANTATION FROM UNRELATED DONORS

      Blood
    78. MORTON AJ; ANASETTI C; GOOLEY T; FLOWERS MED; DEEG HJ; HANSEN JA; MARTIN PJ; SULLIVAN KM
      CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING UNRELATED DONOR TRANSPLANTATION

      Blood
    79. SLATTERY JT; CLIFT RA; BUCKNER CD; RADICH J; STORER B; BENSINGER WI; SOLL E; ANASETTI C; BOWDEN R; BRYANT E; CHAUNCEY T; DEEG HJ; DONEY KC; FLOWERS M; GOOLEY T; HANSEN JA; MARTIN PJ; MCDONALD GB; NASH R; PETERSDORF EW; SANDERS JE; SCHOCH G; STEWART P; STORB R; SULLIVAN KM; THOMAS ED; WITHERSPOON RP; APPELBAUM FR
      MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA - THE INFLUENCE OF PLASMA BUSULFAN LEVELS ON THE OUTCOME OF TRANSPLANTATION

      Blood
    80. ANDERSON JE; GOOLEY TA; SCHOCH G; ANASETTI C; BENSINGER WI; CLIFT RA; HANSEN JA; SANDERS JE; STORB R; APPELBAUM FR
      STEM-CELL TRANSPLANTATION FOR SECONDARY ACUTE MYELOID-LEUKEMIA - EVALUATION OF TRANSPLANTATION AS INITIAL THERAPY OR FOLLOWING INDUCTION CHEMOTHERAPY

      Blood
    81. PETERSDORF EW; LONGTON GM; ANASETTI C; MICKELSON EM; MCKINNEY SK; SMITH AG; MARTIN PJ; HANSEN JA
      ASSOCIATION OF HLA-C DISPARITY WITH GRAFT FAILURE AFTER MARROW TRANSPLANTATION FROM UNRELATED DONORS

      Blood
    82. SIERRA J; STORER B; HANSEN JA; BJERKE JW; MARTIN PJ; PETERSDORF EW; APPELBAUM FR; BRYANT E; CHAUNCEY TR; SALE G; SANDERS JE; STORB R; SULLIVAN KM; ANASETTI C
      TRANSPLANTATION OF MARROW-CELLS FROM UNRELATED DONORS FOR TREATMENT OF HIGH-RISK ACUTE-LEUKEMIA - THE EFFECT OF LEUKEMIC BURDEN, DONOR HLA-MATCHING, AND MARROW CELL DOSE

      Blood
    83. DEEG HJ; LIN DY; LEISENRING W; BOECKH M; ANASETTI C; APPELBAUM FR; CHAUNCEY TR; DONEY K; FLOWERS M; MARTIN P; NASH R; SCHOCH G; SULLIVAN KM; WITHERSPOON RP; STORB R
      CYCLOSPORINE OR CYCLOSPORINE PLUS METHYLPREDNISOLONE FOR PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE - A PROSPECTIVE, RANDOMIZED TRIAL

      Blood
    84. STORB R; LEISENRING W; ANASETTI C; APPELBAUM FR; BUCKNER CD; BENSINGER WI; CHAUNCEY T; CLIFT RA; DEEG HJ; DONEY KC; FLOWERS MED; HANSEN JA; MARTIN PJ; SANDERS KM; WITHERSPOON RP
      LONG-TERM FOLLOW-UP OF ALLOGENEIC MARROW TRANSPLANTS IN PATIENTS WITHAPLASTIC-ANEMIA CONDITIONED BY CYCLOPHOSPHAMIDE COMBINED WITH ANTITHYMOCYTE GLOBULIN

      Blood
    85. MARTIN PJ; PETERSDORF EW; ANASETTI C; HANSEN JA
      HLA HOMOZYGOSITY AND THE RISK OF GRAFT-VERSUS-HOST DISEASE

      Tissue antigens
    86. BENSINGER WI; CLIFT RA; ANASETTI C; APPELBAUM FA; DEMIRER T; ROWLEY S; SANDMAIER BM; TOROKSTORB B; STORB R; BUCKNER CD
      TRANSPLANTATION OF ALLOGENEIC PERIPHERAL-BLOOD STEM-CELLS MOBILIZED BY RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR

      Stem cells
    87. YU XZ; ANASETTI C
      REGULATION OF APOPTOSIS INDUCED BY SOLUBLE ANTI-CD3-F(AB(.))2 IN ANTIGEN-ACTIVATED T-CELLS

      The FASEB journal
    88. SLATTERY JT; KALHORN TF; MCDONALD GB; LAMBERT K; BUCKNER CD; BENSINGER WI; ANASETTI C; APPELBAUM FR
      CONDITIONING REGIMEN-DEPENDENT DISPOSITION OF CYCLOPHOSPHAMIDE AND HYDROXYCYCLOPHOSPHAMIDE IN HUMAN MARROW TRANSPLANTATION PATIENTS

      Journal of clinical oncology
    89. ANDERSON JE; APPELBAUM FR; SCHOCH G; GOOLEY T; ANASETTI C; BENSINGER WI; BRYANT E; BUCKNER CD; CHAUNCEY T; CLIFT RA; DEEG HJ; DONEY K; FLOWERS M; HANSEN JA; MARTIN PJ; MATTHEWS DC; NASH RA; SANDERS JE; SHULMAN H; SULLIVAN KM; WITHERSPOON RP; STORB R
      ALLOGENEIC MARROW TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME WITH ADVANCED DISEASE MORPHOLOGY - A PHASE-II STUDY OF BUSULFAN, CYCLOPHOSPHAMIDE, AND TOTAL-BODY IRRADIATION AND ANALYSIS OF PROGNOSTIC FACTORS

      Journal of clinical oncology
    90. PETERSDORF EW; ANASETTI C; MARTIN PJ; SIERRA J; MICKELSON EM; LONGTON G; GOOLEY T; HANSEN JA
      IMMUNOGENETICS OF ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION

      Experimental hematology
    91. RONDELLI D; HANSEN JA; FORTUNA A; LEMOLI RM; BANDINI G; TURA S; ANASETTI C
      ALLOGENIC T-CELL RESPONSE TO HUMAN RHG-CSF MOBILIZED CD34(-BLOOD CELLS() PERIPHERAL)

      Experimental hematology
    92. DEEG HJ; AMYLON M; COLLINS R; CHAUNCY T; BURDACH S; KAIZER H; GELLER RB; COPELAN E; STORB R; ANASETTI C; HOWE C; MUELLER BA
      MARROW TRANSPLANTATION FROM UNRELATED DONORS (UDT) IN PATIENTS WITH APLASTIC-ANEMIA (AA) WHO HAVE FAILED IMMUNOSUPPRESSIVE THERAPY

      Experimental hematology
    93. ANASETTI C; GOOLEY T; CLIFT R; PETERSDORF E; MARTIN P; HANSEN J
      UNRELATED DONOR MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA (CML)

      Experimental hematology
    94. SLATTERY JT; SANDERS JE; BUCKNER CD; SCHAFFER RL; LAMBERT KW; LANGER FP; ANASETTI C; BENSINGER WI; FISHER LD; APPELBAUM FR; HANSEN JA
      GRAFT-REJECTION AND TOXICITY FOLLOWING BONE-MARROW TRANSPLANTATION INRELATION TO BUSULFAN PHARMACOKINETICS (VOL 16, PG 31, 1995)

      Bone marrow transplantation
    95. MCCARTHY PL; WILLIAMS L; HARRISBACILE M; YEN J; PRZEPIORKA D; IPPOLITI C; CHAMPLIN R; FAY J; BLOSCH C; JACOBS C; ANASETTI C
      A CLINICAL-PHASE I II STUDY OF RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR IN GLUCOCORTICOID-RESISTANT GRAFT-VERSUS-HOST DISEASE/

      Transplantation
    96. WAGNER JL; DEEG HJ; SEIDEL K; ANASETTI C; DONEY K; SANDERS J; SULLIVAN KM; STORB R
      BONE-MARROW TRANSPLANTATION FOR SEVERE APLASTIC-ANEMIA FROM GENOTYPICALLY HLA-NONIDENTICAL RELATIVES - AN UPDATE OF THE SEATTLE EXPERIENCE

      Transplantation
    97. PETERSDORF EW; LONGTON GM; ANASETTI C; MICKELSON EM; SMITH AG; MARTIN PJ; HANSEN JA
      DEFINITION OF HLA-DQ AS A TRANSPLANTATION ANTIGEN

      Proceedings of the National Academy of Sciences of the United Statesof America
    98. YU XZ; ZHU LQ; DAVIS JE; TSO JY; HANSEN JA; ANASETTI C
      INDUCTION OF APOPTOSIS BY ANTI-CD3-EPSILON F(AB')(2) IN ANTIGEN RECEPTOR TRANSGENIC MURINE T-CELLS ACTIVATED BY SPECIFIC PEPTIDE

      The Journal of immunology
    99. ANDERSON JE; ANASETTI C; APPELBAUM FR; SCHOCH G; GOOLEY TA; HANSEN JA; BUCKNER CD; SANDERS JE; SULLIVAN KM; STORB R
      UNRELATED DONOR MARROW TRANSPLANTATION FOR MYELODYSPLASIA (MDS) AND MDS-RELATED ACUTE MYELOID-LEUKEMIA

      British Journal of Haematology
    100. LANGSTON AA; SANDERS JE; DEEG HJ; CRAWFORD SW; ANASETTI C; SULLIVAN KM; FLOWERS MED; STORB R
      ALLOGENEIC MARROW TRANSPLANTATION FOR APLASTIC-ANEMIA ASSOCIATED WITHDYSKERATOSIS-CONGENITA

      British Journal of Haematology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/08/20 alle ore 16:07:05